首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   27227篇
  免费   1853篇
  国内免费   439篇
耳鼻咽喉   185篇
儿科学   1102篇
妇产科学   742篇
基础医学   2080篇
口腔科学   301篇
临床医学   3065篇
内科学   4798篇
皮肤病学   225篇
神经病学   2687篇
特种医学   757篇
外国民族医学   1篇
外科学   2411篇
综合类   3681篇
一般理论   6篇
预防医学   3040篇
眼科学   239篇
药学   2050篇
  15篇
中国医学   385篇
肿瘤学   1749篇
  2023年   562篇
  2022年   800篇
  2021年   1194篇
  2020年   1284篇
  2019年   1002篇
  2018年   972篇
  2017年   979篇
  2016年   941篇
  2015年   944篇
  2014年   2086篇
  2013年   2079篇
  2012年   1654篇
  2011年   1759篇
  2010年   1365篇
  2009年   1313篇
  2008年   1335篇
  2007年   1143篇
  2006年   1039篇
  2005年   830篇
  2004年   710篇
  2003年   638篇
  2002年   565篇
  2001年   476篇
  2000年   436篇
  1999年   381篇
  1998年   317篇
  1997年   281篇
  1996年   243篇
  1995年   273篇
  1994年   237篇
  1993年   195篇
  1992年   205篇
  1991年   169篇
  1990年   149篇
  1989年   139篇
  1988年   128篇
  1987年   95篇
  1986年   71篇
  1985年   104篇
  1984年   87篇
  1983年   56篇
  1982年   48篇
  1981年   30篇
  1980年   29篇
  1979年   39篇
  1978年   27篇
  1977年   21篇
  1976年   19篇
  1975年   15篇
  1973年   15篇
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
1.
IntroductionIdiopathic pulmonary fibrosis (IPF) is progressive and irreversible. Some discrepancies about IPF staging exists, especially in mild phases. Forced vital capacity (FVC) higher than 80% has been considered early or mild IPF even for the design of clinical trials.MethodsSpanish multicentre, observational, retrospective study of IPF patients diagnosed between 2012 and 2016, based on the ATS/ERS criteria, which presented FVC greater or equal 80% at diagnosis. Clinical and demographic characteristics, lung function, radiological pattern, treatment, and follow-up were analyzed.Results225 IPF patients were included, 72.9% were men. The mean age was 69.5 years. The predominant high-resolution computed tomography (HRCT) pattern was consistent usual interstitial pneumonia (UIP) (51.6%). 84.7% of patients presented respiratory symptoms (exertional dyspnea and/or cough) and 33.33% showed oxygen desaturation below 90% in the 6 min walking test (6MWT). Anti-fibrotic treatment was initiated at diagnosis in 55.11% of patients. Median FVC was 89.6% (IQR 17) and 58.7% of patients had a decrease of diffusion lung capacity for carbon monoxide (DLCO) below 60% of theoretical value; most of them presented functional progression (61.4%) and higher mortality at 3 years (20.45%). A statistically significant correlation with the 3-years mortality was observed between DLCO <60% and consistent UIP radiological pattern.ConclusionsPatients with preserved FVC but presenting UIP radiological pattern and moderate–severe DLCO decrease at diagnosis associate an increased risk of progression, death or lung transplantation. Therefore, in these cases, preserved FVC would not be representative of early or mild IPF.  相似文献   
2.
目的:探讨支持-表达性团体辅助对肺癌病人心理弹性、死亡态度及述情障碍的影响。方法:选取2020年3月—2021年3月收治的84例肺癌病人为研究对象,将2020年3月—2020年8月收治的42例肺癌病人作为对照组,将2020年9月—2021年3月收治的42例肺癌病人作为观察组。对照组给予常规肺癌护理,观察组在基础上给予支持-表达性团体辅助干预。观察并比较两组干预前后心理弹性、死亡态度以及述情障碍情况。结果:干预后观察组病人心理弹性中坚韧、力量、乐观维度评分均高于对照组(P<0.05);观察组病人趋近接受、自然接受、逃离接受评分高于对照组,死亡恐惧、死亡逃避评分低于对照组(P<0.05);观察组病人述情障碍各维度评分低于对照组(P<0.05)。结论:支持-表达性团体辅助可提升肺癌病人心理弹性,提高病人自然接受死亡态度,树立正确的生死观,同时降低病人述情障碍。  相似文献   
3.
目的 研究内镜超声检查术(endoscopic ultrasound,EUS)判断早期胃癌浸润深度的准确性及影响因素。方法 回顾性分析2014年1月—2020年8月于北京友谊医院就诊、行EUS且EUS分期为T1的早期胃癌患者的资料。比较EUS与术后病理浸润深度的一致性,计算EUS判断早期胃癌浸润深度的准确率、灵敏度及特异度,并探究影响EUS准确性的相关因素。单因素及多因素分析均采用Logistic回归模型。结果 共纳入380处病变,EUS发现黏膜内(T1a)病变301处,黏膜下层(T1b)病变79处;术后病理实际浸润深度为T1a病变320处,T1b病变60处。EUS判断早期胃癌浸润深度的准确率为77.1%(293/380),灵敏度为83.4%(267/320),特异度为43.3%(26/60)。多因素分析提示,病变位于胃上1/3部(OR=2.272,95%CI:1.266~4.080,P=0.006)、病变长径≥20 mm(OR=2.013,95%CI:1.200~3.377,P=0.008)及低分化癌(OR=2.090,95%CI:1.018~4.294,P=0.045)是影响EUS分期准确性的独立危险因素。低分化癌(OR=4.046,95%CI:1.737~9.425,P=0.001)是EUS过度分期的危险因素。结论 EUS对于早期胃癌浸润深度的判断具有一定的临床应用价值,影响EUS分期准确性的因素包括病变位于胃上1/3部、病变长径≥20 mm及低分化癌,其中低分化癌是EUS过度分期的危险因素。  相似文献   
4.
目的 了解某国家级死因监测点居民死亡漏报情况,评价死因监测信息系统报告的完整性和准确性。 方法 某国家级死因监测点居民死亡信息来源于泸县3个抽样点。采用随机整群抽样的方法,在泸县抽取3个镇(抽样点)共42个村/社,分别从派出所、社事办、妇幼、村(居委会)等渠道收集抽样点2018—2020年全部人口死亡信息,与“人口死因监测信息管理系统”死亡报告数据进行比较,计算漏报率。对“人口死因监测信息管理系统”中抽样点居民死亡报告卡进行审核,评估死因诊断的可靠性和编码质量。 结果 泸县人群总死亡漏报率为9.38%;2018—2020年,漏报率逐渐下降,分别为18.31%、7.53%、2.16%,年度变化百分比为-11.9%,变化趋势差异有统计学意义(t=-5.175,P<0.001),抽样点死因诊断可靠性和准确性较高,可靠诊断单位占比81.81%,可靠诊断依据占比75.67%,根本死因编码错误率为0.21%。 结论 泸县死因监测数据质量较好,但仍需进一步降低漏报率,提高死因监测数据的完整性和诊断的可靠性。  相似文献   
5.
When human remains are discovered, confirming the identification of the decedent is the first part of the forensic medical investigation. In cases where the remains are skeletonised or badly decomposed, differential preservation often increases the difficulty of this task. Bomb pulse dating, which directly compares levels of 14 C within human tissues to atmospheric levels, can provide an estimate of the year of death, which may assist in the identification process. This study measured the 14 C content in samples of hair, nail and puparia collected from donors at the Australian Facility for Taphonomic Experimental Research (AFTER). The radiocarbon results demonstrated that the nail samples provided the most accurate year of death estimation, with 91% correctly predicting YOD, closely followed by hair, with a 79% correct prediction rate, with both hair and nails having a lag time of 0–1 years. This is consistent with the time taken for atmospheric CO 2 to enter the food chain, and be taken in by humans. Puparia was found to have the highest levels of 14 C, and was the least consistent with the actual YOD (46% correct). However, predicted YOD ranges were still within 4 years of the actual YOD. Based on the results of this study, hair, nail and puparia should be considered as useful samples to obtain accurate estimates for YOD using bomb pulse dating.  相似文献   
6.
ObjectiveSeveral trials have recently reported the safety of pulmonary resection after neoadjuvant immunotherapy with encouraging major pathological response rates. We report the detailed adverse events profile from a recently conducted randomized phase II trial in patients with resectable non–small cell lung cancer treated with neoadjuvant durvalumab alone or with sub-ablative radiation.MethodsWe conducted a randomized phase II trial in patients with non–small cell lung cancer clinical stages I to IIIA who were randomly assigned to receive neoadjuvant durvalumab alone or with sub-ablative radiation (8Gyx3). Secondary end points included the safety of 2 cycles of preoperative durvalumab with and without radiation followed by pulmonary resection. Postoperative adverse events within 30 days were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).ResultsSixty patients were enrolled and randomly assigned, with planned resection performed in 26 patients in each arm. Baseline demographics and clinical variables were balanced between groups. The median operative time was similar between arms: 128 minutes (97-201) versus 146 minutes (109-214) (P = .314). There was no 30- or 90-day mortality. Grade 3/4 adverse events occurred in 10 of 26 patients (38%) after monotherapy and in 10 of 26 patients (38%) after dual therapy. Anemia requiring transfusion and hypotension were the 2 most common adverse events. The median length of stay was similar between arms (5 days vs 4 days, P = .172).ConclusionsIn this randomized trial, the addition of sub-ablative focal radiation to durvalumab in the neoadjuvant setting was not associated with increased mortality or morbidity compared with neoadjuvant durvalumab alone.  相似文献   
7.
BackgroundCombining hyperthermic intraperitoneal chemotherapy (HIPEC) treatment with early postoperative intraperitoneal chemotherapy (EPIC) may increase postoperative morbidity. This study aims to investigate postoperative morbidity after HIPEC+EPIC compared with HIPEC alone in patients with peritoneal metastases (PM).Materials and methodsThis is a retrospective propensity score matched cohort study. All patients undergoing PM treatment at Uppsala University Hospital between February 2004 and December 2014 were included. Propensity score matching with a 1:1 ratio was performed using sex, primary tumor site, preoperative chemotherapy, peritoneal cancer index, completeness of cytoreduction score, and HIPEC regimen. Length of hospital stay, morbidity, reoperation rate, and readmission rate within 6 months were selected as endpoints.ResultsA total of 390 consecutive patients were divided in two arms: HIPEC+EPIC (n = 115) and HIPEC alone (n = 275). The propensity score matching (n = 190) was successful with balanced covariates: 95 patients/arm. The length of stay (LOS) was longer in the HIPEC + EPIC group in the total cohort (30 vs 24 days, p < 0.001), with a trend towards significance in the propensity matched group (29 vs 25 days, p = 0.062). No other differences in endpoints were found.ConclusionHIPEC+EPIC is associated with a prolonged hospital stay, but with no statistically significant relevant increase in postoperative morbidity, reoperation rate or incidence of readmission.  相似文献   
8.
PurposeThe purpose of this study was to delineate the effects of variable hormone replacement therapies on neuromotor function in a large cohort of males with 47,XXY from birth to adulthood.MethodsA total of 270 participants aged 16 days to 17 years 11 months prenatally diagnosed with 47,XXY were assessed by their pediatric endocrinologist and were administered hormone replacement therapies accordingly. Infants and school-aged children with 47,XXY were administered neuromotor assessments during routine neurodevelopmental evaluations. For statistical analysis, participants were segregated on the basis of treatment status. Two-tailed t tests, 1-way analysis of variance, and post hoc analysis determined significant group differences on each assessment.ResultsIn infants, the early hormonal treatment (EHT) group performed significantly better than the untreated group on fine motor and motor composite domains. In school-aged children, we observed significantly improved scores on fine motor control, coordination, agility, and strength domains among males treated with EHT (or any combination thereof) compared with those who did not receive early treatment.ConclusionThe highest treated combination group was associated with the highest neuromotor function, although the EHT group also often performed better than the other groups. This suggests EHT may be essential in promoting long-term optimal neuromotor outcome in males with an additional X.  相似文献   
9.
目的 构建肝硬化门静脉高压症并发食管胃底静脉曲张破裂出血(EVB)患者医院内死亡的风险预测模型。方法 2018年6月~2020年6月我院收治的107例肝硬化门静脉高压症并发EVB患者,均接受经颈静脉肝内门体静脉分流术(TIPS)治疗。应用Logistic回归分析影响患者死亡的危险因素,基于独立影响因素构建医院内死亡的风险预测模型,应用Bootstrap法对预测模型进行内部验证,应用受试者工作特征曲线(ROC)下面积(AUC)评估预测模型的预测效能。结果 本组患者医院内死亡25例(23.4%),生存82例;单因素分析显示,死亡患者Child-Pugh分级、出血部位、门静脉内径、肝性脑病和失血性休克发生率等与生存患者比,均存在显著性差异(P<0.05),多因素Logistic回归分析显示,门静脉内径(OR=2.201,95%CI:1.544~3.139)、肝性脑病(OR=3.093,95%CI:1.731~5.524)和失血性休克(OR=1.101,95%CI:1.040~1.165)是影响患者医院内死亡的独立危险因素(P<0.05);对所构建的列线图预测模型,经内部验证,其C-index为0.937(95%CI:0.734~0.879),具有良好的区分度;应用ROC曲线分析显示,预测模型的曲线下面积(AUC)为0.896(95%CI:0.796~0.958,P<0.001),其预测的敏感度和特异度分别为91.3%和88.1%。结论 了解影响肝硬化门静脉高压症并发EVB患者医院内死亡的独立危险因素,并据此构建的风险预测列线图模型具有良好的区分度和预测效能,有助于临床对高风险患者的筛查和及时处理。  相似文献   
10.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号